Articles On Botanix Pharmaceuticals (ASX:BOT)

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has confirmed upcoming presentations of data related to its antimicrobial synthetic cannabidiol program BTX 1801.

Highlights The Australian healthcare sector includes companies engaged in biotechnology and research, food and drug retailing, health care equipment, service providers, and pharmaceuticals. On a YTD basis, the healthcare index is runni...

ASX Emerging Companies (XEC) index has closed 1.5% on Tuesday Index now over 10% the better since February 22 Tuesday winners: ResApp (ASX:RAP), RiversGold (ASX:RGL)    The ASX Emerging Companies (XEC) index is 1.5% higher in late trade....

ShareCafeBotanix Pharmaceuticals (ASX: BOT) – Webinar Presentation Matt Callahan – Executive Director – Botanix Pharmaceuticals is a clinical stage dermatology company developing treatments for common skin diseases and infections. Botanix...

ShareCafeWebinar Recap – BOT, TZL & SLH Catch up on the full webinar with presentations from Botanix Pharmaceuticals (ASX: BOT), TZ Limited (ASX: TZL) & Silk Logistics (ASX: SLH) Webinar Recap – BOT, TZL & SLHCompany News

Botanix Pharmaceuticals (BOT) shares its half yearly report and highlights its dermatology program advancements The company incurred a net loss after income tax of $6,508,794 because of the continued advancement of its dermatology and anti...

Botanix Pharmaceuticals (BOT) has continued progressing multiple clinical programs over the September quarter The healthcare stock began its atopic dermatitis study trialling the BTX 1204A formula of synthetic CBD in up to 45 dogs before i...

FNArena will be updating Special Editions of this Report in September dedicated to the August Reporting Season. An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to...

Massachusetts based cannabis operator MariMed has just announced a joint collaboration with the legendary Boston ice cream brand Emack & Bolio’s® to create a line-up of cannabis-infused vegan and dairy ice cream. The ice cream will cont...

Australia has the potential to become the international gold standard for production of medicinal marijuana and multiple ASX-listed companies are seeking to benefit. -Manufacturing of medicinal cannabis products has been legal in Australia...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is dipping after the company released its latest quarterly report. The cannabinoid-focused pharmaceutical dermatology company’s quarter seemed to be a good one, but the market has reac...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

The 2021 financial year was overall a very good one for ASX shares. The S&P/ASX 200 Index (ASX: XJO) managed to put on a performance of 24% for the 12 months to 30 June 2021. That makes FY2021 one of the best financial years ever for t...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price was a very strong performer on Friday. The clinical stage synthetic cannabinoid company’s shares ended the day a massive 20% higher at 7.8 cents. However, despite this strong gain, the...

Summary ASX-listed digital health company ResApp Health has recruited the first participant in its US-based trial to assess the link between cough and COVID-19. Botanix Pharmaceuticals revealed encouraging results from the BTX 1204A Pi...

Summary Digital health player ResApp Health has entered into a non-exclusive distribution agreement with Ilara Health. Recce Pharmaceuticals stated that RECCE® 327 had shown bactericidal activity against ESKAPE pathogens, including the...

ASX biotechs Recce Pharmaceuticals (ASX:RCE) and Botanix Pharmaceuticals (ASX:BOT) have this morning both given updates on their antimicrobial drug candidates as interest heats up on weapons to combat so-called “superbugs”. Recce said its s...

Summary Medicinal cannabis player Botanix Pharmaceuticals Limited has provided a clinical development update of the BTX 1801 antimicrobial platform. Botanix’s BTX 1801 was safe, well-tolerated, clinically effective in the Phase 2a stud...

Australian clinical dermatology and antimicrobial company Botanix Pharmaceuticals (ASX:BOT) has released a clinical development update of its antimicrobial platform with the identification of a potential new indication.

Summary Digital health behemoth ResMed has released its quarterly results for the March 2021 quarter reporting flat sales. The Company witnessed lower device sales and decreased demand for its ventilators due to COVID-19. However, str...

Botanix Pharmaceuticals (ASX:BOT) says research on the antimicrobial potential of CBD has been supported by the publication of research data from a leading South American academic group in the online journal BioRxiv.

Summary Health House International has signed a non-exclusive distribution agreement with Dragonfly Biosciences. The agreement with Dragonfly would strengthen Health House’s product portfolio within Australia. The distribution agreeme...

Source: photolona, Shutterstock Summary Australian Primary Hemp has signed another retail distribution agreement with Coles Group Limited. Cannabis player Little Green Pharma has entered into a non-exclusive distribution agreement wit...

Source: janews, Shutterstock Summary ASX-listed cannabis player Botanix Pharmaceuticals has obtained ethics approval for BTX 1702 Phase 1b trial. Oncology player PharmAust PharmAust provided an update on its Phase IIb trial evaluating...

Botanix Pharmaceuticals (ASX:BOT) has announced it has received ethics approval for the BTX 1702 Phase 1b clinical study for the treatment of papulopustular rosacea and an expansion of the study design.

Australian clinical-stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has announced the expansion of its management team with the appointment of three executives in the US.

Botanix Pharmaceuticals Ltd (ASX: BOT) shares are flat today following the company’s release of its FY21 half-year results on Friday night. At the time of writing, the Botanix share price is trading at 11 cents, the same price at which it...

Botanix Pharmaceuticals Ltd (ASX: BOT) shares are edging lower today despite the company reporting it has received a research and development (R&D) tax refund. At the time of writing, the Botanix share price has fallen 3.45% lower to 1...

Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has published positive data from a human clinical study examining the safety, tolerability and efficacy of its BTX 1801 antimicrobial product.

Botanix Pharmaceuticals (ASX:BOT) shares have soared after a small clinical trial backed the feasibility of putting synthetic cannabis up the ... Read More The post Botanix soars after pot-up-nose study success appeared first on Stockhead.

Summary Clinical stage synthetic cannabinoid player Botanix Pharmaceuticals has announced positive top-line data from its Phase 2a BTX 1801 study. The Company has also been evaluating the potential for using BTX 1801 for nasal decoloni...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price has returned from its trading halt with a bang on Wednesday. In morning trade, the clinical stage synthetic cannabinoid company’s shares are up 31% to a record high of 19 cents. Why is...

Botanix Pharmaceuticals Ltd (ASX: BOT) shares are lifting off today after the company released its quarterly report. At the time of writing, the Botanix share price is trading 6.06% higher at 17.5 cents. What is driving the Botanix share p...

Despite a brief respite, the pot stock revival looks to still be on the cards. Botanix Pharmaceuticals Ltd [ASX:BOT] was certainly making a strong case for it anyway, with the BOT share price surging 18.5% higher at time of writing... The p...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price has been on fire on Wednesday. At one stage today, the clinical stage synthetic cannabinoid company’s shares were up over 22% to a record high of 16.5 cents. In afternoon trade the Bot...

The research article represents the culmination of research collaborations involving leading antimicrobial researchers across the world.

Botanix Pharmaceuticals shares are on the rise after research showed that a synthetic cannabidiol formulation can kill so-called "superbugs". ... Read More The post Botanix collab with UQ confirms antimicrobial potential of CBD appeared fir...

The pot stock resurgence isn’t slowing down yet! Cannabis companies are still going strong. With biotech-focused Botanix Pharmaceuticals Ltd [ASX:BOT] leading the charge this morning... The post Botanix Share Price Rises 4% as Clinical Stud...

The company is developing a pipeline of product candidates that leverage the antimicrobial properties of cannabinoids with a BTX 1801 Phase 2a study for the prevention of surgical site infections well advanced.

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is trading higher today on news the company has completed its phase 2a clinical study for BTX 1801. In mid-morning trade, the Botanix share price was up 8% to 13.5 cents. It has since...

Summary Botanix Pharmaceuticals has completed BTX 1801 antimicrobial Phase 2a clinical study. The Company anticipates top-line data of the study to be available early in the next year. BTX 1801 Phase 2a clinical study was intended to...

Clinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) says it has successfully completed a Pre-Investigational New Drug meeting with the US FDA's Office of Infectious Diseases for its lead antimicrobial program, BTX 1...

Summary Cannabinoid pharmaceutical player Botanix Pharmaceuticals has completed a pre-IND meeting with the FDA’s Office of Infectious Diseases for clinical development of BTX 1801. The US regulatory body stated that the proposed plan an...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is surging higher today after a positive announcement. In the minutes after market open, shares in the synthetic cannabinoid company jumped as high as 11.5 cents. The Botanix share pri...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is soaring higher today following the release of its September quarter update. At the time of writing, the synthetic cannabinoid company’s shares are up 15% to a year-high of 11.5 cent...

The ASX is littered with lots of companies that show potential to become the next market darling. While I mostly invest in the mid-to-large cap space, I do look for small cap ASX shares that could deliver strong returns. Every company has...

ASX cannabis stocks are continuing their victory lap following yesterday’s decision by the TGA to re-classify low-dose cannabidiol (CBD) products. The TGA has made an interim decision to down schedule CBD products, including oil and pills,...

Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) says it has conducted an 'end of phase two' meeting with the US FDA in relation to the development of BTX 1503 for the treatment of moderate and severe a...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price surged more than 20% higher in early trade after the company released an announcement regarding a milestone achievement. What did Botanix announce? Prior to the market’s open this morn...